Equities

OrganiGram Holdings Inc

OrganiGram Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.68
  • Today's Change0.08 / 3.08%
  • Shares traded424.46k
  • 1 Year change-4.29%
  • Beta1.1045
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Organigram Holdings Inc. operates through its subsidiaries. The Company’s major wholly owned subsidiaries include Organigram Inc., 10870277 Canada Inc., The Edibles and Infusions Corporation (EIC), and Laurentian Organic Inc. (Laurentian). Organigram Inc. is a licensed producer (LP) of cannabis, cannabis-derived products and cannabis infused edibles in Canada. It is focused on producing cannabis for patients and adult recreational consumers, as well as developing international business partnerships. It has also developed and owns a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. It operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. 10870277 Canada Inc. is a special purpose holding company for the Company. EIC is a cannabis processor of confectionary goods.

  • Revenue in CAD (TTM)154.77m
  • Net income in CAD-269.68m
  • Incorporated2016
  • Employees984.00
  • Location
    OrganiGram Holdings Inc35A English Dr.MONCTON E1E 3X3CanadaCAN
  • Phone+1 (506) 384-1571
  • Fax+1 (604) 484-7155
  • Websitehttps://www.organigram.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arch Biopartners Inc1.85m-1.95m139.16m--------75.34-0.0312-0.03120.0296-0.0912.73--4.38---288.23-214.82---------105.69-180.45---3.94----105.63---136.30------
Eupraxia Pharmaceuticals Inc0.00-38.55m140.68m29.00--35.68-----1.60-1.600.000.1110.00----0.00-147.08-127.84-307.19-935.99-----------25.650.9213-------52.63---7.69--
NervGen Pharma Corp0.00-22.38m143.66m10.00---------0.3772-0.37720.00-0.03370.00-------120.62-121.15-380.82-180.20-----------3.86---------8.01--2.20--
Zentek Ltd33.61k-11.98m155.85m27.00--6.96--4,636.96-0.1197-0.11970.00030.22280.00130.07960.08761,244.82-44.53-41.94-48.53-44.46-573.70---35,636.60-12,771.314.27--0.0538---79.01--54.52--39.27--
Cardiol Therapeutics Inc0.00-28.13m169.57m17.00--5.76-----0.4363-0.43630.000.43220.00-------56.98-58.97-69.77-68.62-------158,738.10----0.0061------9.06--36.06--
Cipher Pharmaceuticals Inc28.91m27.85m211.81m6.008.111.927.177.331.091.091.134.590.26481.593.56--25.5121.5328.0827.4080.7783.5896.3257.318.62--0.00440.002.36-1.44-23.4876.18-53.51--
OrganiGram Holdings Inc154.77m-269.68m275.84m984.00--0.8437--1.78-3.37-3.371.893.180.35492.225.77165,532.60-61.84-23.49-68.43-25.39-21.04-6.87-174.24-97.372.11--0.0005--10.8667.04-1,640.54---11.62--
Data as of Apr 23 2024. Currency figures normalised to OrganiGram Holdings Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.